人 IRF9 抗体对
01AB03236
Interferon regulatory factor 9 (IRF9) is a crucial transcription factor in the immune response, particularly in mediating the effects of type I interferons (IFNs). It forms part of the ISGF3 complex, which includes STAT1 and STAT2, and is essential for the transcriptional activation of interferon-stimulated genes (ISGs) that drive antiviral responses. IRF9 is characterized by its DNA-binding domain, which allows it to interact with specific promoter elements to regulate gene expression. Beyond its role in antiviral immunity, IRF9 has been implicated in various diseases, including autoimmune disorders and cancers. Dysregulation of IRF9 can lead to inappropriate activation of immune responses, contributing to conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Additionally, altered IRF9 activity has been associated with tumor progression and metastasis in certain cancers.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- IRF9
- 基因别名
- ISGF3G
- 蛋白别名
- interferon regulatory factor 9; IRF9
- UniProt
- Q00978
- 物种
- Human
产品详情
- 靶点名称
- IRF9
- 蛋白名称
- interferon regulatory factor 9
- 蛋白别名
- Interferon regulatory factor 9; IRF-9; IFN-alpha-responsive transcription factor subunit; ISGF3 p48 subunit; Interferon-stimulated gene factor 3 gamma; ISGF-3 gamma; Transcriptional regulator ISGF3 subunit gamma
- 靶点基因名
- IRF9
- 基因别名
- ISGF3G
- UniProt
- Q00978
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Interferon regulatory factor 9 (IRF9) is a crucial transcription factor in the immune response, particularly in mediating the effects of type I interferons (IFNs). It forms part of the ISGF3 complex, which includes STAT1 and STAT2, and is essential for the transcriptional activation of interferon-stimulated genes (ISGs) that drive antiviral responses. IRF9 is characterized by its DNA-binding domain, which allows it to interact with specific promoter elements to regulate gene expression. Beyond its role in antiviral immunity, IRF9 has been implicated in various diseases, including autoimmune disorders and cancers. Dysregulation of IRF9 can lead to inappropriate activation of immune responses, contributing to conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Additionally, altered IRF9 activity has been associated with tumor progression and metastasis in certain cancers.